摘要
目的分析比较瑞舒伐他汀与阿托伐他汀对急性冠状动脉综合征患者的临床作用。方法选取2017年10月—2018年12月就诊的急性冠状动脉综合征患者100例,按治疗药物不同分为阿托伐他汀组和瑞舒伐他汀组,每组50例。阿托伐他汀组给予阿托伐他汀40 mg/d口服,瑞舒伐他汀组给予瑞舒伐他汀20 mg/d口服,连续用药4周。比较2组治疗前后的C-反应蛋白(CRP)、红细胞沉降率(ESR)以及血脂水平,比较2组的心血管不良事件和不良反应发生情况。结果治疗后,2组CRP和ESR水平均较治疗前明显降低,且瑞舒伐他汀组CRP水平低于阿托伐他汀组(P<0.05)。治疗后,2组总胆固醇和低密度脂蛋白胆固醇水平均较治疗前明显降低(P<0.05),而高密度脂蛋白胆固醇和甘油三酯水平与治疗前比较差异无统计学意义(P>0.05)。2组复发性心绞痛发生率和不良反应总发生率比较差异均无统计学意义(P>0.05)。结论瑞舒伐他汀与阿托伐他汀均能在短期内有效降低ACS患者的CRP、ESR和血脂水平,其中瑞舒伐他汀在降低CRP方面更有效,且2种药物的安全性均较高。
Objective To compare clinical effect between Rosuvastatin and Atorvastatin in treatment of patients with acute coronary syndrome.Methods A total of 100 patients with acute coronary syndrome treated during October 2017 and December 2018 were divided into Atorvastatin group and Rosuvastatin group(n=50 in each group)according to different therapeutic drugs.Atorvastatin group was given 40 mg/d Atorvastatin orally,while Rosuvastatin group was given 20 mg/d Rosuvastatin orally,and all patients received continuous treatments for 4 weeks.Levels of C-reactive protein(CRP),erythrocyte sedimentation rate(ESR)and blood lipid before and after treatment were compared,and incidence rates of cardiovascular adverse events and adverse reactions were compared between two groups.Results After treatment,CRP and ESR levels were significantly lower than those before treatment in two groups,and CRP level in Rosuvastatin group was significantly lower than that in Atorvastatin group(P<0.05).After treatment in two groups,levels of total cholesterol and low-density lipoprotein cholesterol were significantly lower than those before treatment(P<0.05),but there were no significant differences in levels of high-density lipoprotein cholesterol and triglyceride before and after treatment in two groups(P>0.05).There were no significant differences in incidence rate of recurrent angina pectoris and the total incidence rate of adverse reactions between two groups(P>0.05).Conclusion Both Rosuvastatin and Atorvastatin may effectively reduce CRP,ESR and blood lipid levels in patients with acute coronary syndrome in a short period.Among them,Rosuvastatin is more effective in reducing CRP level,and both drugs have good safety.
作者
田田
赵殿儒
贾媛媛
马桂英
杨震
罗建平
高丽萍
TIAN Tian;ZHAO Dian-ru;JIA Yuan-yuan;MA Gui-ying;YANG Zhen;LUO Jian-ping;GAO Li-ping(Department of Cardiology,People's Hospital of Cangzhou City,Cangzhou,Hebei 061001,China;Department of Clinical Laboratory,People's Hospital of Cangzhou City,Cangzhou,Hebei 061001,China;Department of Cardiology,General Hospital of Beijing Jingmei Group,Beijing 102300,China;Department of Paediatrics,Hospital of Yuanshi County,Yuanshi,Hebei 051130,China)
出处
《解放军医药杂志》
CAS
2019年第12期57-59,68,共4页
Medical & Pharmaceutical Journal of Chinese People’s Liberation Army
基金
河北省卫生厅科研基金项目(20181135)
沧州市重点研发计划指导项目(172302058)
